According to a recent study, Aromasin worsened bone loss in post-menopausal women, raising the chance of fractures and calling into question whether the pill’s prevention benefits outweigh its risks.
In a trial among 351 women at risk of developing breast cancer, those who received Aromasin lost about three times more bone-mineral density after two years than those who took a placebo, researchers wrote in The Lancet Oncology.
Find it here: http://www.lancet.com/journals/lanonc/issue/current
